Pandemic Perspectives: NCATS Director Urges Rare Disease Community To Push Against Return To Clinical Trial Status Quo

Chris Austin argued the rare disease community deserves the same “movement of heaven and earth” mentality as was employed for COVID-19.

Planes, with one going in another direction
Time and resources still will be needed to determine the best pandemic-inspired clinical trial innovations. • Source: Shutterstock

Chris Austin believes stakeholders will have to protect the coronavirus-inspired changes to the clinical trial system from an establishment longing to return to the status quo once the pandemic subsides.

The director of the US National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) said the pandemic has...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Rare Diseases

More from Pink Sheet